Browsing by Author "Olanipekun, O.C."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Quality Assessment of different Brands of Diclofenac Tablets Marketed in Ilorin metropolis: a Pharmaceutical and Health Perspective(Pharmaceutical Society of Nigeria, 2020) Abdullahi, S.T.; Olanipekun, O.C.; Njinga, N.S.; Eniayewu, O.I.; Bamidele, O.D.; Bakare-Odunnola, M.T.; Shittu, A.O.; Soyinka, J.O.Background: The quality of a medicinal product is an important factor for its safety and efficacy. Poor-quality medicines are a major impediment to improvements in public health. This study assessed the pharmaceutical quality of different brands of diclofenac (DCF) tablets in Ilorin metropolis. Methods: Four randomly selected brands of diclofenac potassium tablets (coded: DCF-A, DCF-B, DCF-C and DCF-D) were obtained from pharmaceutical outlets, and quality parameters were evaluated according to Pharmacopeial methods. The potency of tablets was determined spectrophotometrically based on the measurement of maximum absorbance at a wavelength of 276 nm in doubly distilled water. Results: Method validation according to the International Council for Harmonization guidelines showed acceptable sensitivity (limit of detection of 0.3886 pg/mL and limit of quantification of 1.1775 pg/mL), precision (% relative standard deviation range of 0.72 — 1.54), accuracy (% recovery range of 98.9— 101.3). Average contents of active diclofenac were 45, 98, 103 and 105% for DCF-A, DCF-B, DCF-C and DCF-D respectively. DCF-A brand was not only substandard but falsified based on British Pharmacopoeia potency specification range of 95 — 105%. Conclusion: A substandard and falsified brand of diclofenac tablets was detected. Drug regulatory authority must ensure periodic post-registration surveillance of licensed pharmaceutical products marketed in the country to secure the health and safety of the populace.Item Quality assessment of different brands of diclofenac tablets marketed in Ilorin metropolis: a pharmaceutical and public health perspective(Nigerian Journal of Pharmacy. Published by the Pharmaceutical Society of Nigeria., 2020-04) Abdullahi, S.T; Olanipekun, O.C.; Eniayewu, O.I; Bamidele, O.D; Bakare-Odunola, M.T; Shittu, A.O; Soyinka, J.O.Background: The quality of a medicinal product is an important factor for its safety and efficacy. Poor-quality medicines are a major impediment to improvements in public health. This study assessed the pharmaceutical quality of different brands of diclofenac (DCF) tablets in Ilorin metropolis. Methods: Four randomly selected brands of diclofenac potassium tablets (coded: DCF-A, DCF-B, DCF-C and DCF-D) were obtained from pharmaceutical outlets, and quality parameters were evaluated according to Pharmacopeial methods. The potency of tablets was determined spectrophotometrically based on the measurement of maximum absorbance at a wavelength of 276 nm in doubly distilled water. Results: Method validation according to the International Council for Harmonization guidelines showed acceptable sensitivity (limit of detection of 0.3886 μg/mL and limit of quantication of 1.1775 μg/mL), precision (% relative standard deviation range of 0.72 – 1.54), accuracy (% recovery range of 98.9 – 101.3). Average contents of active diclofenac were 45, 98, 103 and 105% for DCF-A, DCF-B, DCF-C and DCF-D respectively. DCF-A brand was not only substandard but falsied based on British Pharmacopoeia potency specication range of 95 – 105%. Conclusion: A substandard and falsied brand of diclofenac tablets was detected. Drug regulatory authority must ensure periodic post-registration surveillance of licensed pharmaceutical products marketed in the country to secure the health and safety of the populace.Item Quality assessment of different brands of diclofenac tablets marketed in Ilorin metropolis: a pharmaceutical and public health perspective.(Nigerian Journal of Pharmacy. Published by Pharmaceutical Society of Nigeria., 2020) Abdullahi, S.T.; Olanipekun, O.C.; Njinga, N.S.,; Eniayewu, O.I.; Bamidele, O.D.; Bakare-Odunola, M.T.; Shittu, A.O.; Soyinka, J.O.Background: The quality of a medicinal product is an important factor for its safety and efficacy. Poor-quality medicines are a major impediment to improvements in public health. This study assessed the pharmaceutical quality of different brands of diclofenac (DCF) tablets in Ilorin metropolis. Methods: Four randomly selected brands of diclofenac potassium tablets (coded: DCF-A, DCF-B, DCF-C and DCF-D) were obtained from pharmaceutical outlets, and quality parameters were evaluated according to Pharmacopeial methods. The potency of tablets was determined spectrophotometrically based on the measurement of maximum absorbance at a wavelength of 276 nm in doubly distilled water. Results: Method validation according to the International Council for Harmonization guidelines showed acceptable sensitivity (limit of detection of 0.3886 μg/mL and limit of quantication of 1.1775 μg/mL), precision (% relative standard deviation range of 0.72 – 1.54), accuracy (% recovery range of 98.9 – 101.3). Average contents of active diclofenac were 45, 98, 103 and 105% for DCF-A, DCF-B, DCF-C and DCF-D respectively. DCF-A brand was not only substandard but falsied based on British Pharmacopoeia potency specication range of 95 – 105%. Conclusion: A substandard and falsied brand of diclofenac tablets was detected. Drug regulatory authority must ensure periodic post-registration surveillance of licensed pharmaceutical products marketed in the country to secure the health and safety of the populace.